cemiplimab (Libtayo) is an anti-pd1 immunotherapy indicated for the treatment of patients with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. This drug is an immune checkpoint inhibitor that targets PD-1, a protein on immune system cells (called T cells), that normally helps keep these cells from attacking other cells in the body. By blocking PD-1, this drug boosts the immune response restoring antitumor activity. cemiplimab (Libtayo) is given as an intravenous (IV) infusion.
- for more information visit Sanofi Genzyme Canada
The most common adverse reactions from this drug include fatigue, rash, and diarrhea. It’s very important to report any new side effects during or after treatment to your health care team promptly.
Provincial Funding Summary
Libtayo™ (cemiplimab) Receives Positive Recommendation from the pan-Canadian Oncology Drug Review Expert Review Committee for the Treatment of Metastatic Cutaneous Squamous Cell Carcinoma
Visit CADTH The pan-Canadian Oncology Drug Review (pCODR) reivew status for Libtayo. CADTH is an evidence-based, cancer drug review process. The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada’s provinces and territories (except Quebec) in guiding their drug funding decisions.
Learn about treatments available in Canada for cSCC patients. Click Here
Cutaneous Squamous Cell Carcinoma (cSCC) Patient Forum
Ask questions or learn from others. Join our online patient community by visiting MNC cSCC forum